Planned Parenthood closing 4 Minnesota health centers amid federal funding threats
Planned Parenthood North Central States (PPNCS) is closing eight health centers and laying off dozens of staff members in the wake of major funding cuts by the Trump administration.
The reproductive and sexual health provider said that it will close four locations in Minnesota and four in Iowa as it consolidates its operations.
It will result in 66 staff being laid off, and another 37 being offered reassignment, with the organization having already reduced its head count by 35 through gradual attrition.
The health centers closing over the coming year are as follows:
Ames Health Center – Ames, Iowa
Alexandria Health Center – Alexandria, Minnesota
Apple Valley Health Center – Apple Valley, Minnesota
Bemidji Health Center – Bemidji, Minnesota
Cedar Rapids Health Center – Cedar Rapids, Iowa
Richfield Health Center – Richfield, Minnesota
Sioux City Health Center – Sioux City, Iowa
Urbandale Health Center – Urbandale, Iowa
That will leave 10 locations remaining in Minnesota:
Brooklyn Park Health Center
Duluth Health Center
Eden Prairie Health Center
Mankato Health Center
Minneapolis Health Center
Moorhead Health Center
Rochester Health Center
St. Cloud Health Center
St. Paul Health Center - Vandalia
Rice Street Health Center (St. Paul)
The organization claims that the changes come as "patient needs and preferences have changed, the broken aspects of our health care system have intensified, the organization's Minnesota Title X funds have been frozen, and the U.S. House voted to advance a reconciliation package that defunds Planned Parenthood."
PPNCS says that it was informed in April that $2.8 million of Title X funding in Minnesota was frozen, saying it was the "only federal program dedicated to providing affordable birth control and other reproductive health care to people no matter the person's income or insurance status."
"The Health and Human Services budget now proposes additional severe cuts, including the elimination of the Teen Pregnancy Prevention Program which provides over $773,000 annually for education and outreach in Iowa and Nebraska," it adds.
"Meanwhile, Congress is advancing a reconciliation package that would defund Planned Parenthood and slash Medicaid – threatening access to care for the more than 30% of our patients who rely on Medicaid, among other impacts."
Reproductive health care has become increasingly targeted for funding cuts by Republicans, intensifying following the overturning of Roe v. Wade by the Supreme Court in 2022, ending federal protections for abortion care.
Planned Parenthood, which provides a number of sexual health and women's services outside of abortion, claims the restructuring will allow it to "build a strong network of health centers that consistently deliver expert sexual and reproductive health care," saying the centers that remain currently serve 82% of its patient population.
"My heart hurts as we announce the closure of health centers and the departure of trusted and talented colleagues, but our patients come first—always," said Ruth Richardson, President and CEO of Planned Parenthood North Central States.
"We have been fighting to hold together an unsustainable infrastructure as the landscape shifts around us and an onslaught of attacks continues. We know that many of our patients would have nowhere to turn if every Planned Parenthood health center were to disappear from their state. Heart wrenching and hard decisions today will ensure Planned Parenthood is here for years to come. Make no mistake: care may look different but Planned Parenthood North Central States is here to stay."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 hours ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
CNN
3 hours ago
- CNN
China to make all hospitals offer epidurals to incentivize childbirth
China said that by the end of this year all tertiary level hospitals must offer epidural anesthesia during childbirth, a move it said would help promote a 'friendly childbearing environment' for women. Tertiary hospitals – those with more than 500 beds – must provide epidural anesthesia services by 2025 while secondary hospitals – those containing more than 100 beds – must provide the services by 2027, China's National Health Commission (NHC) said in a statement last week. Authorities are struggling to boost birth rates in the world's second largest economy after China's population fell for a third consecutive year in 2024 with experts warning the downturn will worsen in the coming years. Around 30% of pregnant women in China receive anesthesia to relieve pain during childbirth, compared with more than 70% in some developed countries, the official China Daily said. The World Health Organization recommends epidurals for healthy pregnant women requesting pain relief and it is widely utilized in many countries around the world, including France, where around 82% of pregnant women opt to have one, and in the United States and Canada where more than 67% do. The move will 'improve the comfort level and security of medical services' and 'further enhance people's sense of happiness and promote a friendly childbearing environment,' the NHC said. A growing number of provinces across China are also beginning to include childbirth anesthesia costs as part of their medical insurance schemes to encourage more women to have children. High childcare costs as well as job uncertainty and a slowing economy have discouraged many young Chinese from getting married and starting a family. In June, health authorities in China's southwestern Sichuan province proposed to extend marriage leave up to 25 days and maternity leave up to 150 days, to help create a 'fertility-friendly society.'
Medscape
3 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
